- Report
- February 2018
- 160 Pages
Global
From €2000EUR$2,200USD£1,698GBP
- Report
- June 2021
- 129 Pages
Global
From €2500EUR$2,750USD£2,123GBP
€4999EUR$5,500USD£4,245GBP
- Drug Pipelines
- July 2020
- 33 Pages
Global
From €3181EUR$3,500USD£2,701GBP
- Drug Pipelines
- January 2020
- 112 Pages
Global
From €3181EUR$3,500USD£2,701GBP
- Report
- March 2024
- 30 Pages
Global
From €2500EUR$2,750USD£2,123GBP
- Report
- August 2022
- 151 Pages
Global
From €8635EUR$9,500USD£7,333GBP
- Report
- August 2022
- 75 Pages
Global
From €4317EUR$4,750USD£3,666GBP
- Report
- December 2023
- 163 Pages
Global
From €2272EUR$2,500USD£1,930GBP
- Report
- February 2022
- 44 Pages
Global
From €3181EUR$3,500USD£2,701GBP
- Drug Pipelines
- October 2018
- 98 Pages
Global
From €3181EUR$3,500USD£2,701GBP
- Report
- October 2018
- 17 Pages
Global
From €9089EUR$10,000USD£7,718GBP
- Book
- November 2024
- 464 Pages
- Book
- May 2023
- 512 Pages
- Book
- May 2023
- 512 Pages
- Book
- July 2018
- 360 Pages
The Phosphoinositide 3 Kinase (PI3K) market is a subset of the oncology drug market. PI3K inhibitors are a type of targeted therapy used to treat cancer. They work by blocking the activity of the PI3K enzyme, which is involved in the growth and spread of cancer cells. PI3K inhibitors are used to treat a variety of cancers, including breast, ovarian, and lung cancer. They are also used in combination with other treatments, such as chemotherapy and radiation therapy.
PI3K inhibitors are a relatively new type of cancer treatment, and the market is still in its early stages. However, the potential of PI3K inhibitors to improve outcomes for cancer patients has led to increased investment in the development of new drugs. Several companies are currently developing PI3K inhibitors, including AstraZeneca, Novartis, and Pfizer. Show Less Read more
